InspireMD, Inc.NSPR

InspireMD, Inc. (NSPR) is a medical technology outfit that pitches itself as the guardian of carotid arteries, with a signature product called CGuard® EPS-a mesh stent designed to provide “sustained embolic protection.” The company’s website, product pages, and investor materials are polished with patents, trial updates, and a heroic narrative of innovation aimed at vascular disease. Yet the latest 10-Q for the quarter ending 31 March 2026 shows a company whose revenues were a mere $3.4 million against a net loss of $13.7 million, with diluted EPS of negative sixteen cents. The gap between the stent-adjacent slide deck and the actual filings is wide enough to park a small ambulance in.

CGuard® EPS is explicitly described as “investigational” in the United States, meaning the firm’s marquee product has not yet cleared the FDA’s gate. InspireMD is nonetheless advancing a Premarket Approval (PMA) Supplement in the U.S. and has initiated the CGUARDIANS III clinical trial, both of which are costly undertakings that burn cash and dilute shares. The company spent $4.8 million on R&D in the quarter while its inventory shrank by $360,000 to $3.0 million, neither figure suggesting a product ramp on the near horizon. The company’s cash position sat at $11.4 million at 31 March 2026, enough for a runway but not enough for a product launch party.

The 10-Q confirms: revenue from contract with customer excluding tax was $3.4M; net loss attributable to parent was $-13.7M; operating loss was $-14.0M; assets totalled $56.5M; liabilities $12.9M; stockholders’ equity $43.6M; cash and equivalents $11.4M; net cash used in operating activities $-12.3M; capex $194k; R&D expense $4.8M; inventory net $3.0M with a decrease of $360k; diluted EPS $-0.16; and weighted average diluted shares 83.8M. These are not projections; they are the contents of the company’s latest quarterly filing.

InspireMD’s product, CGuard® EPS, is a dual-layer mesh carotid stent designed to trap debris during stenting procedures and thereby reduce stroke risk. The company touts patents and clinical programmes, but the U.S. market remains off-limits until FDA clearance. The company’s official rails include product pages, patent listings, and press releases touting trial initiation and PMA submission, all of which describe a pipeline rather than a commercial business. The evidence does not show any FDA clearance, CE mark expansion, or revenue line item from CGuard® EPS in the latest quarter.

The stock trades on the Tel Aviv Stock Exchange under ticker NSPR, where liquidity is thin and volatility can spike on headlines rather than fundamentals. The company’s latest 8-K filings disclose governance updates and clinical-trial initiation, but none provide revenue, cash receipts, or commercial milestones. The absence of a clear revenue path, thin cash runway, and reliance on equity issuance to fund operations are the salient facts. Until CGuard® EPS gains regulatory clearance and commercial traction, the company’s story remains one of promise rather than performance.

The company’s ownership structure, as presented in the SEC’s ownership XML for 29 May 2026, shows a dispersed shareholder base with no single holder above disclosure thresholds, reinforcing the thin-liquidity dynamic. The evidence base does not include analyst coverage, valuation commentary, or institutional support, indicating the name is followed by a niche audience rather than mainstream funds. The SEC submissions JSON confirms the filing cadence but adds no new financial data beyond what is captured in the 10-Q.